erbB in NSCLC as a molecular target: current evidences and future directions

A number of treatments have been developed for HER1, 2 and 3-driven non-small cell lung cancer (NSCLC), of which the most successful have been the epidermal growth factor receptor-tyrosine kinase inhibitors in HER1-mutant tumours resulting in highly improved progression-free survival. Human epiderma...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:ESMO Open
Huvudupphovsmän: Del Re, Marzia, Cucchiara, Federico, Petrini, Iacopo, Fogli, Stefano, Passaro, Antonio, Crucitta, Stefania, Attili, Ilaria, De Marinis, Filippo, Chella, Antonio, Danesi, Romano
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2020
Ämnen:
Review
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7443272/
https://ncbi.nlm.nih.gov/pubmed/32820012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000724
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk